Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 11/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523917 | 0.88 | BTN3A1 (0.45) | BTN3A1ANPEPLAP3ELANEPRTN3 | |
| SCHEMBL523916 | 0.88 | BTN3A1 (0.45) | BTN3A1ANPEPLAP3ELANEPRTN3 | |
| SCHEMBL807682 | 0.88 | BTN3A1 (0.57) | BTN3A1ANPEPLAP3ALDH1A1TSHR | |
| SCHEMBL21158533 | 0.88 | BTN3A1 (0.57) | BTN3A1ANPEPLAP3ALDH1A1TSHR | |
| SCHEMBL14466574 | 0.88 | BTN3A1 (0.57) | BTN3A1ANPEPLAP3ALDH1A1TSHR | |
| SCHEMBL23992573 | 0.88 | BTN3A1 (0.57) | BTN3A1ANPEPLAP3ALDH1A1TSHR | |
| SCHEMBL12900849 | 0.86 | BTN3A1 (0.43) | BTN3A1ANPEPLAP3ALDH1A1ELANE | |
| SCHEMBL25387275 | 0.86 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL23992574 | 0.86 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL800889 | 0.86 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513061-B | 4' -Thio-nucleotides and-nucleoside prodrugs for treating cancer | 南方研究院 | 2025-01-24 | — | — | CN | disclosed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| WO-2019204637-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | SOUTHERN RESEARCH INSTITUTE (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2696679-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| WO-2013084165-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| WO-2012142093-A2 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885ANPEP 361/4885LAP3 2159/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885ANPEP 361/4885LAP3 2159/4885 |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HCCS, NSUN2, PNP | BTN3A1 2370/4885ANPEP 424/4885LAP3 2661/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | BTN3A1 4056/4885ANPEP 361/4885LAP3 2159/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | BTN3A1 1701/4885ANPEP 227/4885LAP3 1954/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | BTN3A1 2837/4885ANPEP 244/4885LAP3 2080/4885 |
| US-20130143835-A1 | HCV Polymerase Inhibitors | POLI, HAVCR2, EIF2AK2 | BTN3A1 3624/4885ANPEP 202/4885LAP3 619/4885 |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | POLI, HAVCR2, EIF2AK2 | BTN3A1 3624/4885ANPEP 202/4885LAP3 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.